Compare Johnson Controls International PLC (JCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs TG Therapeutics Inc — how do they compare? Johnson Controls International PLC trades at $142.46 (market cap $86.46B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Johnson Controls International PLC is far larger — about 10.5× TG Therapeutics Inc's market cap, and Johnson Controls International PLC pays a 1.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JCI | TGTX | |
|---|---|---|
Market Cap | $86.46B | $8.26B |
Sector | Industrials | Health |
52-Week High | $148.21 | $59.06 |
52-Week Low | $103.24 | $26.39 |
Enterprise Value | $95.28B | $8.50B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $141.71, up 0.89% with a bearish technical signal but strong analyst support. Recent earnings beats and a 14.45% net margin highlight operational strength, while valuation metrics like a P/E of 42.62 suggest premium pricing. The company maintains a dividend and benefits from positive news flow, including industry awards and strategic appointments.
Outlook is mixed: bullish fundamentals and analyst consensus target of $158.29 offer upside, but technical weakness and high valuation pose risks. Key drivers include execution in building systems and data center demand, while debt levels and economic sensitivity require monitoring for sustained growth.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
